Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms

Oncogene

Volumn 28, Issue 10, 2009, Pages 1309-1319

  Hollmen M ^a,b   Maatta J A ^a   Bald, L ^c   Sliwkowski, M X ^c   Elenius, K ^a,b,d  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c GENENTECH INC   (United States)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Ectodomain shedding; EGFR; HER4; Neuregulins; Therapeutic antibodies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1479; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL STRAIN COS7; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL PROLIFERATION; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 62249111362     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.481     Document Type: Article

References (46)

1. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137.
2. Bao J, Wolpowitz D, Role LW, Talmage DA. (2003). Back signaling by the Nrg-1 intracellular domain. J Cell Biol 161: 1133-1141.
3. Borrell-Pages M, Rojo F, Albanell J, Baselga J, Arribas J. (2003). TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO J 22: 1114-1124.
4. Carter P. (2001). Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1: 118-129.
5. Cheng QC, Tikhomirov O, Zhou W, Carpenter G. (2003). Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. J Biol Chem 278: 38421-38427.
6. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney Jr DW et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
7. Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069-1075.
8. Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD et al. (1997). A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J Biol Chem 272: 26761-26768.
9. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328.
10. Furger C, Fiddes RJ, Quinn DI, Bova RJ, Daly RJ, Sutherland RL. (1998). Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. Cancer Res 58: 1773-1778.
11. Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H et al. (2002). ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8: 3054-3064.
12. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. (1997). Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57: 3272-3280.
13. Gilmore JL, Riese II DJ. (2004). secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol Res 14: 589-602.
14. Gomes AQ, Ali BR, Ramalho JS, Godfrey RF, Barral DC, Hume AN et al. (2003). Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell 14: 1882-1899.
15. Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR. (1996). Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res 56: 1184-1188.
16. Hynes NE, Lane HA. (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
17. Iivanainen E, Paatero I, Heikkinen SM, Junttila TT, Cao R, Klint P et al. (2007). Intra- and extracellular signaling by endothelial neuregulin-1. Exp Cell Res 313: 2896-2909.
18. Junttila TT, Laato M, Vahlberg T, Soderstrom KO, Visakorpi T, Isola J et al. (2003). Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res 9: 5346-5357.
19. Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Harkonen P et al. (2005). Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res 65: 1384-1393.
20. Junttila TT, Sundvall M, Maatta JA, Elenius K. (2000). Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 10: 304-310.
21. Kainulainen V, Sundvall M, Maatta JA, Santiestevan E, Klagsbrun M, Elenius K. (2000). A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 275: 8641-8649.
22. Katz M, Shtiegman K, Tal-Or P, Yakir L, Mosesson Y, Harari D et al. (2002). Ligand-independent degradation of epidermal growth factor receptor involves receptor ubiquitylation and Hgs, an adaptor whose ubiquitin-interacting motif targets ubiquitylation by Nedd4. Traffic 3: 740-751.
23. Klapper LN, Waterman H, Sela M, Yarden Y. (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60: 3384-3388.
24. Komuro A, Nagai M, Navin NE, Sudol M. (2003). WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278: 33334-33341.
25. Lee HJ, Jung KM, Huang YZ, Bennett LB, Lee JS, Mei L et al. (2002). Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. J Biol Chem 277: 6318-6323.
26. Määttä JA, Sundvall M, Junttila TT, Peri L, Laine VJ, Isola J et al. (2006). Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell 17: 67-79.
27. Mendelsohn J, Baselga J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565.
28. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749.
29. Ni CY, Murphy MP, Golde TE, Carpenter G. (2001). gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294: 2179-2181.
30. Omerovic J, Santangelo L, Puggioni E, Marrocco J, Dall'Armi C, Palumbo C et al. (2007). The E3 ligase Aip4/Itch ubiquitinates and targets ErbB-4 for degradation. FASEB J 21: 2849-2862.
31. Paatero I, Elenius K. (2008). ErbB4 and its isoforms: patentable drug targets? Recent Pat DNA Gene Seq 2: 27-33.
32. Paborsky LR, Fendly BM, Fisher KL, Lawn RM, Marks BJ, McCray G et al. (1990). Mammalian cell transient expression of tissue factor for the production of antigen. Protein Eng 3: 547-553.
33. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L et al. (1993). Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750.
34. Prewett M, Rothman M, Waksal H, Feldman M, Bander NH, Hicklin DJ. (1998). Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4: 2957-2966.
35. Rio C, Buxbaum JD, Peschon JJ, Corfas G. (2000). Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 275: 10379-10387.
36. Schlessinger J, Lemmon MA. (2006). Nuclear signaling by receptor tyrosine kinases: the first robin of spring. Cell 127: 45-48.
37. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
38. Srinivasan R, Benton E, McCormick F, Thomas H, Gullick WJ. (1999). Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res 5: 2877-2883.
39. Srinivasan R, Poulsom R, Hurst HC, Gullick WJ. (1998). Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185: 236-245.
40. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. (1986). Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83: 3825-3829.
41. Sundvall M, Iljin K, Kilpinen S, Sara H, Kallioniemi O, Elenius K. (2008a). Role of ErbB4 in breast cancer. J Mammary Gland Biol Neoplasia 13: 259-268.
42. Sundvall M, Korhonen A, Paatero I, Gaudio E, Melino G, Croce C et al. (2008b). Isoform-specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms. Proc Natl Acad Sci USA 105: 4162-4167.
43. Sundvall M, Peri L, Maatta JA, Tvorogov D, Paatero I, Savisalo M et al. (2007). Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene 26: 6905-6914.
44. Vecchi M, Baulida J, Carpenter G. (1996). Selective cleavage of the heregulin receptor ErbB-4 by protein kinase C activation. J Biol Chem 271: 18989-18995.
45. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. (2003). Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297.
46. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A et al. (1996). Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem 271: 3884-3890.